Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies

Launched by OSLO UNIVERSITY HOSPITAL · Feb 25, 2014

Keywords

ClinConnect Summary

This clinical trial is focused on understanding and improving treatment options for patients with certain types of cancers that affect the lining of the abdomen, known as peritoneal surface malignancies. These include conditions like pseudomyxoma peritonei, colorectal cancer, ovarian cancer, and mesothelioma. The main goal is to find specific markers that can help predict whether the disease might come back after surgery and to determine the best candidates for a particular treatment approach called cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Researchers will also explore different treatment strategies using animal models to see what might work best.

To join this trial, participants need to be at least 18 years old, have a confirmed diagnosis of one of the targeted cancers, and be considered suitable for the CRS-HIPEC treatment. There are no specific exclusions mentioned, so most patients who meet these criteria can participate. The study is currently recruiting and expects to enroll about 80 patients each year. Participants can expect to receive specialized care and contribute to important research that could lead to better treatment options for themselves and future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age \> 18 years
• • confirmed diagnosis of peritoneal surface malignancy
• • candidate for CRS-HIPEC
• • written informed consent
• Exclusion Criteria:
• • none
• • Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.